JMIR Bioinformatics and Biotechnology,
Journal Year:
2024,
Volume and Issue:
5, P. e62752 - e62752
Published: Oct. 16, 2024
An
increasing
body
of
literature
highlights
the
integration
machine
learning
with
genomic
data
in
psychiatry,
particularly
for
complex
mental
health
disorders
such
as
schizophrenia.
These
advanced
techniques
offer
promising
potential
uncovering
various
facets
these
disorders.
A
comprehensive
review
current
applications
conjunction
within
this
context
can
significantly
enhance
our
understanding
state
research
and
its
future
directions.
Advanced Science,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 6, 2025
Drug
repurposing
identifies
new
therapeutic
uses
for
the
existing
drugs
originally
developed
different
indications,
aiming
at
capitalizing
on
established
safety
and
efficacy
profiles
of
known
drugs.
Thus,
it
is
beneficial
to
bypass
early
stages
drug
development,
reduction
time
cost
associated
with
bringing
therapies
market.
Traditional
experimental
methods
are
often
time-consuming
expensive,
making
artificial
intelligence
(AI)
a
promising
alternative
due
its
lower
cost,
computational
advantages,
ability
uncover
hidden
patterns.
This
review
focuses
availability
AI
algorithms
in
their
positive
specific
roles
revealing
drugs,
especially
being
integrated
virtual
screening.
It
shown
that
excel
analyzing
large-scale
datasets,
identifying
complicated
patterns
responses
from
these
predictions
potential
repurposing.
Building
insights,
challenges
remain
developing
efficient
future
research,
including
integrating
drug-related
data
across
databases
better
repurposing,
enhancing
efficiency,
advancing
personalized
medicine.
Schizophrenia Research,
Journal Year:
2024,
Volume and Issue:
268, P. 193 - 204
Published: March 16, 2024
There
is
a
relative
lack
of
research
evaluating
the
outcomes
when
treatment
guidelines
or
algorithms
for
psychotic
disorders
are
followed.
This
systematic
review
and
meta-analysis
determined
response
rates
to
antipsychotic
medications
at
different
stages
these
whether
differ
in
first
episode
cohorts.
Frontiers in Psychiatry,
Journal Year:
2025,
Volume and Issue:
16
Published: March 18, 2025
Schizophrenia
is
a
severe
mental
disorder
with
strong
lifetime
impact
on
patients'
health
and
wellbeing.
Usually,
symptomatic
treatment
includes
typical
or
atypical
antipsychotics.
Study
findings
show
an
involvement
of
low-grade
inflammation
(blood,
brain
parenchyma,
cerebrospinal
fluid)
in
schizophrenia.
Moreover,
experimental
neuropathological
evidence
suggests
that
reactive
microglia,
which
are
the
main
resident
immune
cells
central
nervous
system
(CNS),
have
negative
differentiation
function
oligodendrocytes,
glial
progenitor
cells,
astrocytes,
results
disruption
neuronal
networks
dysregulated
synaptic
transmission,
contributing
to
pathophysiology
Here,
role
microglial
related
neuroinflammation
schizophrenia
was
discussed
be
essential.
This
review
aims
summarize
for
influence
antipsychotics
inflammatory
mechanisms
Furthermore,
we
propose
established
astrocyte-microglia
co-culture
model
testing
regulatory
examining
effects
glia-mediated
neuroinflammation.
could
lead
better
understanding
how
can
used
address
positive
symptoms
comorbidities
like
diseases
status
inflammation.
Pharmacological Research,
Journal Year:
2025,
Volume and Issue:
unknown, P. 107718 - 107718
Published: March 1, 2025
Recent
clinical
trial
successes
in
schizophrenia
with
non-dopaminergic
agents
have
rejuvenated
the
field
after
a
long
period
of
unsuccesfull
attempts.
At
same
time,
non-invasive
neurostimulation
has
been
increasingly
applied
other
mental
health
disorders
while
few
studies
performed
schizophrenia.
The
time
arrived
to
consider
combining
psychotherapy
neuromodulation.
However,
systematic
approach
optimize
designs
is
needed.
"Computational
Psychiatry"
defined
as
computational
neuroscience
modeling
using
biophysically
and
anatomically
realistic
representations
key
brain
areas
based
on
neuroimaging
data
biological
knowledge.
In
this
position
paper,
we
will
expand
concept
include
drug
exposure
pharmacology
combination
This
can
be
used
impact
active
platform
generates
new
silico
biomarker,
"information
bandwidth",
that
might
related
outcomes
assumption
information
processing
capacity
human
represented
by
measure
entropy
quantifies
level
uncertainty
associated
processes.
Previously
shown
readout
model
closed
cortical-striatal-thalamocortical
loop
highly
correlated
changes
positive
symptoms
antipsychotic
treatment.
paper
present
strategy
how
expanded
Computational
Psychiatry
support
optimization
design
neuromodulation
psychopharmacology,
well
understanding
mitigating
placebo
response.
Journal of Clinical Psychopharmacology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 8, 2025
Abstract
Purpose/Background
Clozapine
was
approved
in
the
United
States
(US)
using
1989
regulations
and
knowledge.
After
30
years,
many
sections
of
US
package
insert
(PI)
are
outdated.
Methods
We
comprehensively
reviewed
literature
to
propose
PI
updates.
present
information
2
articles.
In
Part
I,
we
focus
on
basic
pharmacology
based
407
relevant
II
focuses
clinical
aspects
pharmacovigilance.
Findings/Results
Based
more
recent
expectations
Food
Drug
Administration
regulations,
clozapine
including
following:
1)
clearance,
2)
pharmacokinetics
pharmacodynamics,
3)
monitoring
tools.
identified
9
major
problems
pharmacological
vivo
studies
indicate
that
is
dependent
CYP1A2
for
its
metabolism,
minor
role
CYP2D6
metabolism
requires
removing
recommendation
lower
doses
poor
metabolizers,
nontoxic
concentrations
CYP3A4
has
a
potent
inhibitors
lack
clinically
effects,
4)
several
drug-drug
interactions
need
be
updated
literature,
5)
systemic
inflammation
may
decrease
increase
risk
intoxication,
6)
obesity
7)
patients
Asian
Indigenous
American
ancestry
doses,
8)
personalized
titration
c-reactive
protein
should
considered
until
prospective
available,
9)
half-life
section
needs
modified
acknowledge
single
dosing
at
night
frequent
US.
Implications/Conclusions
An
improvement
lead
PIs
worldwide.
